{"url_path":"/sec/cocp/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1412486/0001493152-26-023377-index.html","accession_number":"0001493152-26-023377","cik":"0001412486","ticker":"COCP","issuer_name":"Cocrystal Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1412486/0001493152-26-023377-index.html","primary_entity_key":"0001412486","primary_entity_name":"Cocrystal Pharma, Inc."},"word_count":719,"has_tables":true,"body_markdown":"false\n--12-31\nQ1\n0001412486\n\n0001412486\n\n2026-01-01\n2026-03-31\n\n0001412486\n\n2026-05-15\n\n0001412486\n\n2026-03-31\n\n0001412486\n\n2025-12-31\n\n0001412486\n\nus-gaap:RelatedPartyMember\n\n2026-03-31\n\n0001412486\n\nus-gaap:RelatedPartyMember\n\n2025-12-31\n\n0001412486\n\n2025-01-01\n2025-03-31\n\n0001412486\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001412486\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001412486\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001412486\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001412486\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001412486\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001412486\n\n2024-12-31\n\n0001412486\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001412486\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001412486\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001412486\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001412486\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001412486\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001412486\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001412486\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001412486\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001412486\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001412486\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001412486\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001412486\n\n2025-03-31\n\n0001412486\n\n2025-10-01\n2025-10-31\n\n0001412486\n\nCOCP:OutstandingOptionsToPurchaseCommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001412486\n\nCOCP:OutstandingOptionsToPurchaseCommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001412486\n\nCOCP:WarrantsToPurchaseCommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001412486\n\nCOCP:WarrantsToPurchaseCommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001412486\n\nCOCP:UnvestedRestrictedStockUnitsMember\n\n2026-01-01\n2026-03-31\n\n0001412486\n\nCOCP:UnvestedRestrictedStockUnitsMember\n\n2025-01-01\n2025-03-31\n\n0001412486\n\nsrt:MinimumMember\n\n2026-03-31\n\n0001412486\n\nsrt:MaximumMember\n\n2026-03-31\n\n0001412486\n\nCOCP:LabEquipmentMember\n\n2026-03-31\n\n0001412486\n\nCOCP:LabEquipmentMember\n\n2025-12-31\n\n0001412486\n\nCOCP:FinanceLeaseRightofUseLabEquipmentNetMember\n\n2026-03-31\n\n0001412486\n\nCOCP:FinanceLeaseRightofUseLabEquipmentNetMember\n\n2025-12-31\n\n0001412486\n\nCOCP:ComputerAndOfficeEquipmentMember\n\n2026-03-31\n\n0001412486\n\nCOCP:ComputerAndOfficeEquipmentMember\n\n2025-12-31\n\n0001412486\n\nCOCP:SecuritiesPurchaseAgreementMember\n\n2025-09-12\n2025-09-12\n\n0001412486\n\nCOCP:SecuritiesPurchaseAgreementMember\n\n2025-09-12\n\n0001412486\n\nCOCP:SecuritiesPurchaseAgreementMember\nCOCP:InvestorWarrantsMember\n\n2025-09-12\n\n0001412486\n\nCOCP:SecuritiesPurchaseAgreementMember\nCOCP:PlacementAgentWarrantsMember\n\n2025-09-12\n2025-09-12\n\n0001412486\n\nCOCP:SecuritiesPurchaseAgreementMember\nCOCP:PlacementAgentWarrantsMember\n\n2025-09-12\n\n0001412486\n\nCOCP:TwoThousandandFifteenEquityIncentivePlansMember\n\n2026-03-31\n\n0001412486\n\nCOCP:TwoThousandandFifteenEquityIncentivePlansMember\n\n2026-01-01\n2026-03-31\n\n0001412486\n\nCOCP:TwoThousandandFifteenEquityIncentivePlansMember\n\n2021-06-15\n\n0001412486\n\nCOCP:TwoThousandandFifteenEquityIncentivePlansMember\n\n2021-06-16\n\n0001412486\n\nCOCP:TwoThousandandTwentyFiveEquityIncentivePlansMember\n\n2025-04-02\n\n0001412486\n\nCOCP:TwoThousandandTwentyFiveEquityIncentivePlansMember\n\n2025-04-02\n2025-04-02\n\n0001412486\n\nCOCP:TwoThousandandTwentyFiveEquityIncentivePlansMember\nsrt:MinimumMember\n\n2025-04-02\n2025-04-02\n\n0001412486\n\nCOCP:TwoThousandandTwentyFiveEquityIncentivePlansMember\nsrt:MaximumMember\n\n2025-04-02\n\n0001412486\n\nCOCP:TwoThousandandTwentyFiveEquityIncentivePlansMember\n\n2026-01-01\n2026-03-31\n\n0001412486\n\nus-gaap:EmployeeStockOptionMember\n\n2026-01-01\n2026-01-31\n\n0001412486\n\nus-gaap:EmployeeStockOptionMember\n\n2026-01-09\n\n0001412486\n\nus-gaap:EmployeeStockOptionMember\n\n2026-01-31\n\n0001412486\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2024-08-12\n\n0001412486\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2024-08-12\n2024-08-12\n\n0001412486\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2026-03-31\n\n0001412486\n\nus-gaap:EmployeeStockOptionMember\n\n2025-12-31\n\n0001412486\n\nus-gaap:EmployeeStockOptionMember\n\n2026-01-01\n2026-03-31\n\n0001412486\n\nus-gaap:EmployeeStockOptionMember\n\n2026-03-31\n\n0001412486\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2025-12-31\n\n0001412486\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2026-01-01\n2026-03-31\n\n0001412486\n\n2023-04-01\n\n0001412486\n\n2023-04-01\n2023-04-01\n\n0001412486\n\n2023-09-01\n\n0001412486\n\n2023-09-01\n2023-09-01\n\n0001412486\n\n2024-08-01\n\n0001412486\n\n2024-08-01\n2024-08-01\n\n0001412486\n\nus-gaap:RelatedPartyMember\n\n2026-01-01\n2026-03-31\n\n0001412486\n\nus-gaap:RelatedPartyMember\n\n2025-01-01\n2025-03-31\n\n0001412486\n\nCOCP:DrPhillipFrostMember\n\n2024-08-14\n2024-08-14\n\n0001412486\n\nCOCP:DrPhillipFrostMember\n\n2024-08-14\n\n0001412486\n\nCOCP:DrPhillipFrostMember\n\n2026-03-31\n\n0001412486\n\nCOCP:DrPhillipFrostMember\n\n2026-01-01\n2026-03-31\n\n0001412486\n\nCOCP:DrPhillipFrostMember\n\n2025-01-01\n2025-03-31\n\n0001412486\n\n2025-01-01\n2025-06-30\n\n0001412486\n\nCOCP:SegmentsMember\n\n2026-01-01\n2026-03-31\n\n0001412486\n\nCOCP:SegmentsMember\n\n2025-01-01\n2025-03-31\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\nCOCP:Segment\n\nutr:sqft\n\n \n\n \n\n** **\n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**WASHINGTON,\nD.C. 20549**\n\n \n\n**FORM\n10-Q**\n\n \n\n☒\n**QUARTERLY\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe quarterly period ended March 31, 2026**\n\n \n\n**OR**\n\n \n\n☐\n**TRANSITION\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe transition period from to**\n\n \n\n**Commission\nfile number: 001-38418**\n\n \n\n**COCRYSTAL\nPHARMA, INC.**\n\n*(Exact\nname of registrant as specified in its charter)*\n\n \n\n**Delaware**\n \n**35-2528215**\n\n*(State\nor Other Jurisdiction of*\n \n*(I.R.S.\nEmployer*\n\n*Incorporation\nor Organization)*\n \n*Identification\nNo.)*\n\n \n \n \n\n**19805\nNorth Creek Parkway Bothell, WA**\n \n**98011**\n\n*(Address\nof Principal Executive Office)*\n \n*(Zip\nCode)*\n\n \n\nRegistrant’s\ntelephone number, including area code: **877-262-7123**\n\n \n\nIndicate\nby check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post\nsuch files). Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”\n“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):\n\n \n\nLarge\naccelerated filer\n☐\nAccelerated\nfiler\n☐\n\n \n \n \n \n\nNon-accelerated\nfiler\n☒\nSmaller\nreporting company\n☒\n\n \n \n \n \n\nEmerging\ngrowth company\n☐\n \n \n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act:\n\n \n\n**Title\nof Each Class**\n \n**Trading\nSymbol(s)**\n \n**Name\nof each exchange on which registered**\n\nCommon\nStock\n \nCOCP\n \n\nThe\nNasdaq Stock Market LLC\n\n(The\nNasdaq Capital Market)\n\n \n\nAs\nof May 15, 2026, the number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was approximately\n13,787,453.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**COCRYSTAL\nPHARMA, INC.**\n\n \n\n**FORM\n10-Q FOR THE QUARTER ENDED MARCH 31, 2026**\n\n \n\n**INDEX**\n\n \n\n[Part\nI - FINANCIAL INFORMATION](#a_001)"}